AR134579A2 - Proceso para la preparación de un compuesto de diariltiohidantoína - Google Patents

Proceso para la preparación de un compuesto de diariltiohidantoína

Info

Publication number
AR134579A2
AR134579A2 ARP240103372A ARP240103372A AR134579A2 AR 134579 A2 AR134579 A2 AR 134579A2 AR P240103372 A ARP240103372 A AR P240103372A AR P240103372 A ARP240103372 A AR P240103372A AR 134579 A2 AR134579 A2 AR 134579A2
Authority
AR
Argentina
Prior art keywords
preparation
diarylthiohydantoin compound
compound
diarylthiohydantoin
intermediates
Prior art date
Application number
ARP240103372A
Other languages
English (en)
Inventor
Cyril Ben Haim
Andras Horvath
Johan Erwin Edmond Weerts
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of AR134579A2 publication Critical patent/AR134579A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen los procesos e intermedios para la preparación del Compuesto (X), que se investiga actualmente para el tratamiento del cáncer de próstata.
ARP240103372A 2014-12-19 2024-12-06 Proceso para la preparación de un compuesto de diariltiohidantoína AR134579A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19

Publications (1)

Publication Number Publication Date
AR134579A2 true AR134579A2 (es) 2026-01-28

Family

ID=55168400

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150104237A AR103228A1 (es) 2014-12-19 2015-12-21 Proceso para la preparación de un compuesto de diariltiohidantoína
ARP240103372A AR134579A2 (es) 2014-12-19 2024-12-06 Proceso para la preparación de un compuesto de diariltiohidantoína

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP150104237A AR103228A1 (es) 2014-12-19 2015-12-21 Proceso para la preparación de un compuesto de diariltiohidantoína

Country Status (33)

Country Link
US (1) US9688655B2 (es)
EP (4) EP3372585B1 (es)
JP (2) JP6681902B2 (es)
KR (1) KR102586059B1 (es)
CN (2) CN118638097A (es)
AR (2) AR103228A1 (es)
AU (1) AU2015364537B2 (es)
BR (1) BR112017013113B1 (es)
CY (3) CY1121684T1 (es)
DK (3) DK3233803T3 (es)
EA (4) EA201892486A1 (es)
ES (3) ES2827549T3 (es)
HR (3) HRP20190540T1 (es)
HU (2) HUE052475T2 (es)
IL (1) IL252843B2 (es)
LT (3) LT3233803T (es)
MA (1) MA41200B1 (es)
MD (1) MD3233803T2 (es)
ME (1) ME03420B (es)
MX (1) MX375467B (es)
NZ (1) NZ732766A (es)
PH (1) PH12017501152B1 (es)
PL (3) PL3372584T3 (es)
PT (3) PT3233803T (es)
RS (3) RS61060B9 (es)
SG (4) SG10201912811QA (es)
SI (3) SI3372585T1 (es)
SM (3) SMT202000618T1 (es)
TR (1) TR201904739T4 (es)
TW (4) TWI689494B (es)
UA (1) UA123201C2 (es)
WO (1) WO2016100652A2 (es)
ZA (1) ZA201704877B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233823B1 (en) * 2014-12-19 2019-01-30 Aragon Pharmaceuticals, Inc. Processes for the preparation of a diarylthiohydantoin compound
ME03420B (me) * 2014-12-19 2020-01-20 Aragon Pharmaceuticals Inc Postupak za pripremu jedinjenja diariltiohidantoina
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
CN108383749B (zh) * 2018-01-30 2021-03-09 杭州科巢生物科技有限公司 阿帕鲁胺的合成方法及其中间体
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN110511206A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN110511207A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN113968815B (zh) * 2020-07-24 2025-11-18 苏州科伦药物研究有限公司 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
JP7815242B2 (ja) * 2020-11-20 2026-02-17 アムジエン・インコーポレーテツド ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンを調製するためのプロセス
CN113402466B (zh) * 2021-06-18 2022-08-16 南京方生和医药科技有限公司 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法
CN113292535B (zh) * 2021-06-18 2022-07-01 南京方生和医药科技有限公司 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法
CN115572264B (zh) * 2021-07-06 2025-12-05 山东新时代药业有限公司 一种恩杂鲁胺的制备方法
CN115850233B (zh) * 2021-09-24 2024-12-10 南京方生和医药科技有限公司 一种阿帕鲁胺的合成方法
CN116239536A (zh) * 2021-12-08 2023-06-09 山东新时代药业有限公司 一种阿帕鲁胺中间体化合物
CN117534652A (zh) * 2022-08-02 2024-02-09 黄冈人福药业有限责任公司 一种阿帕他胺的制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
CN117645572A (zh) * 2023-11-23 2024-03-05 奥锐特药业股份有限公司 恩扎卢胺及其中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
TWI445707B (zh) * 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
US8722695B2 (en) 2009-12-11 2014-05-13 Autifony Therapeutics Limited Imidazolidinedione derivatives
HUE037389T2 (hu) * 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
ES2671343T3 (es) * 2010-02-24 2018-06-06 Medivation Prostate Therapeutics Llc Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína
WO2012119559A1 (en) 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
CN104379160A (zh) * 2012-03-29 2015-02-25 桑加特公司 双阿司匹林交联聚乙二醇化血红蛋白
CA2908326C (en) * 2013-05-29 2017-09-12 Hinova Pharmaceuticals Inc. Imidazolidinedione compounds and their uses
ME03420B (me) * 2014-12-19 2020-01-20 Aragon Pharmaceuticals Inc Postupak za pripremu jedinjenja diariltiohidantoina

Also Published As

Publication number Publication date
TW201639825A (zh) 2016-11-16
KR20170095976A (ko) 2017-08-23
RS61060B1 (sr) 2020-12-31
LT3372585T (lt) 2022-07-11
ES2919951T3 (es) 2022-07-29
UA123201C2 (uk) 2021-03-03
SI3233803T1 (sl) 2019-05-31
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (pl) 2021-07-05
JP2018501237A (ja) 2018-01-18
SG10201912811QA (en) 2020-02-27
CN107108507B (zh) 2024-05-28
EP3372585A1 (en) 2018-09-12
EP3372584B1 (en) 2020-09-23
ZA201704877B (en) 2019-02-27
TWI703132B (zh) 2020-09-01
HRP20190540T1 (hr) 2019-06-14
TW201945343A (zh) 2019-12-01
ME03420B (me) 2020-01-20
SI3372585T1 (sl) 2022-08-31
EP3372584A1 (en) 2018-09-12
IL252843B1 (en) 2024-10-01
AU2015364537A1 (en) 2017-07-06
EA201892487A1 (ru) 2019-07-31
HRP20220750T1 (hr) 2022-09-02
MX375467B (es) 2025-03-06
RS58454B1 (sr) 2019-04-30
HRP20201847T2 (hr) 2021-05-28
DK3372585T3 (da) 2022-05-30
HUE052475T2 (hu) 2021-05-28
CY1123611T1 (el) 2022-03-24
TWI683810B (zh) 2020-02-01
SMT202200242T1 (it) 2022-07-21
PL3233803T3 (pl) 2019-07-31
CY1121684T1 (el) 2020-07-31
TWI689494B (zh) 2020-04-01
HUE042409T2 (hu) 2019-06-28
LT3233803T (lt) 2019-04-10
MD3233803T2 (ro) 2019-07-31
DK3372584T3 (da) 2021-01-04
EA201892485A1 (ru) 2019-07-31
PH12017501152B1 (en) 2022-04-29
JP6903785B2 (ja) 2021-07-14
SG11201704969QA (en) 2017-07-28
TW202031639A (zh) 2020-09-01
EP3372586A1 (en) 2018-09-12
PT3372584T (pt) 2020-11-13
AU2015364537B2 (en) 2020-10-08
ES2827549T3 (es) 2021-05-21
US9688655B2 (en) 2017-06-27
CN118638097A (zh) 2024-09-13
RS61060B9 (sr) 2021-07-30
EP3372585B1 (en) 2022-03-30
EP3233803B1 (en) 2019-01-30
BR112017013113A2 (pt) 2017-12-26
US20160176845A1 (en) 2016-06-23
IL252843A0 (en) 2017-08-31
IL252843B2 (en) 2025-02-01
BR112017013113B1 (pt) 2023-11-21
CA2970937A1 (en) 2016-06-23
TWI753336B (zh) 2022-01-21
PL3372585T3 (pl) 2022-10-10
SG10201912805SA (en) 2020-02-27
ES2718539T3 (es) 2019-07-02
JP6681902B2 (ja) 2020-04-15
LT3372584T (lt) 2020-12-10
EP3372584B9 (en) 2021-03-31
MX2017008179A (es) 2017-09-18
EA201892486A1 (ru) 2019-07-31
JP2020114842A (ja) 2020-07-30
NZ732766A (en) 2023-07-28
HRP20201847T1 (hr) 2021-03-19
TW201945342A (zh) 2019-12-01
WO2016100652A2 (en) 2016-06-23
SMT201900208T1 (it) 2019-05-10
EP3233803A2 (en) 2017-10-25
RS63455B1 (sr) 2022-08-31
CN107108507A (zh) 2017-08-29
KR102586059B1 (ko) 2023-10-05
MA41200A (fr) 2017-10-25
DK3233803T3 (en) 2019-04-08
ES2827549T9 (es) 2021-07-02
AR103228A1 (es) 2017-04-26
WO2016100652A3 (en) 2016-08-25
PT3372585T (pt) 2022-07-08
SMT202000618T1 (it) 2021-01-05
SI3372584T1 (sl) 2021-08-31
SG10201912802XA (en) 2020-02-27
MA41200B1 (fr) 2019-05-31
EA201791390A1 (ru) 2017-10-31
DK3372584T5 (da) 2021-05-17
TR201904739T4 (tr) 2019-05-21
PT3233803T (pt) 2019-05-20
CY1125243T1 (el) 2025-03-28

Similar Documents

Publication Publication Date Title
AR134579A2 (es) Proceso para la preparación de un compuesto de diariltiohidantoína
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
MX2019012734A (es) Procesos para la preparacion de un compuesto de diariltiohidantoina.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
SV2019005822A (es) Metodos para tratar el cáncer de próstata
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
PH12017501879A1 (en) Methods for treating cancer
UY36286A (es) Tratamientos médicos basados en anamorelina
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
MX2017008373A (es) Compuestos, composiciones y metodos.
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
CL2019000214A1 (es) Métodos para tratar el cáncer de próstata.